1 / 25

Highlights from the 14 th Annual Report

Highlights from the 14 th Annual Report. Catriona Shaw Research Fellow UK Renal Registry. UKRR Audit Day , October 2012. demography. UK incident RRT rates between 1980 and 2010. Median age of incident patients in each centre in 2010. Prevalence rate of RRT patients per million population

leone
Télécharger la présentation

Highlights from the 14 th Annual Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights from the 14th Annual Report Catriona Shaw Research Fellow UK Renal Registry UKRR Audit Day, October 2012

  2. demography UK incident RRT rates between 1980 and 2010

  3. Median age of incident patients in each centre in 2010

  4. Prevalence rate of RRT patients per million population by age and gender on 31/12/2010

  5. Population aged 65 and over, 2011 England and Wales local and unitary authorities

  6. Ethnicity and standardised prevalence ratios for all PCT/HB areas by percentage non-White on 31/12/2010 (excluding areas with <5% ethnic minorities)

  7. Age profile of prevalent RRT patients by modality on 31/12/2010

  8. Co morbidity Growth in prevalent patients by treatment modality at the end of each year 1997–2010 • Changes 2005-2010 • (pmp) • -5.9% PD, • +4.1% HD, • +4.6% Tx Growth of home haemodialysis +23% (2010 data)

  9. Mean comorbidity score by age group Fotheringham, J et al. UKRR Annual Report 2012

  10. survival Trend in 1 year after 90 day survival by first established modality 2003–2009 (adjusted to age 60) (excluding patients whose first modality was transplantation)

  11. Kaplan–Meier survival of incident patients 1997–2009 cohort (from day 90), without censoring at transplantation

  12. Survival one-year after 90 days, adjusted to age 60, 2009 incident cohort

  13. Median age of incident CKD5 and incident RRT patients by renal centre Ford, D et al UKRR Annual Report 2010, Nephron Clinical Practice +Unpublished work

  14. International comparison of RRT incidence rates in 2009 Data from USRDS

  15. Haematological and biochemical parameters Funnel plot of percentage of HD patients with Hb ≥10 and ≤12 g/dl by centre in 2010

  16. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit measure (1.1–1.7mmol/L) by centre in 2010

  17. Funnel plot of percentage of haemodialysis patients with PTH within range (16–32 pmol/L) by centre in 2010

  18. Transplant population • Increase in renal transplantation from all sources of organs • Inclusion of eGFR slopes in the analysis for the first time • 9734 individuals included in eGFR slope analysis • Steeper slopes were seen in females, ethnic minorities, diabetes, younger individuals

  19. Cause of death by modality for prevalent patients on 1/1/2010

  20. Infective complications Box and whisker plot of MRSA rates by renal centre per 100 prevalent HD/PD patients by reporting year

  21. Number of MSSA bacteraemia episodes by access and renal centre: 1/01/2011 to 30/06/2011

  22. 1995: Treatment of adult patients with renal failureRecommended standards and audit measures

  23. opportunities • CKD stage 5 patients to understand conservative and withdrawal issues to allow adjustment for survival and other outcomes (quality of life) • AKI • Challenge our current boundaries in therapies • Specific need for research focused on improving outcomes in the elderly multi-morbid population • New collaborations with external organisations (CPRD, allied renal industries)- help improve drug data, examine outcomes, pragmatic RCT’s?, causal inference methodologies

  24. WE ARE ALL GETTING BETTER AT STOPPING DEATH IN CKD Our GP, cardiac and diabetology colleagues will safely carry CKD patients into the hands of nephrologists

More Related